Shortages of Adderall (mixed amphetamine salts), the renowned treatment for attention deficit hyperactivity disorder and narcolepsy, and its generic equivalents is now headline news in the US, with widespread reports of patients being told that prescriptions are on backorder for up to several months.
Sandoz Weighs In On US Adderall Shortages Amid Supply Disruption
As Patients Wait Up To Three Months To Collect Prescriptions
A spike in demand for Adderall and its generic versions has left patients scrambling to have their prescriptions filled, making headline news in the US. Leading generics manufacturer Sandoz told Generics Bulletin its current experience amid the supply squeeze.
More from Generics
• By
Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.
• By
Speaking as Hypera delivered its full year-results, CEO Breno Oliveira has set out plans for the Brazilian firm to launch an Ozempic rival in its domestic market next year. Meanwhile, the company is dealing with increasingly aggressive local generic competition.
• By
Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”
More from Products
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).
• By
Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
With an ambitious goal to file a biosimilar to the world-renowned Botox brand via the US FDA’s 351(k) regulatory pathway, AEON Biopharma has revealed the latest steps in its plan.